These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34729217)

  • 21. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.
    Patel PH; Kockler DR
    Ann Pharmacother; 2008 Jan; 42(1):91-8. PubMed ID: 18094343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry.
    Wei XX; Kwak L; Hamid A; He M; Sweeney C; Flanders SC; Harmon M; Choudhury AD
    Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):314-319. PubMed ID: 35145218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
    Sims RB
    Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809).
    McNeel DG; Chen YH; Gulley JL; Dwyer AJ; Madan RA; Carducci MA; DiPaola RS
    Hum Vaccin Immunother; 2015; 11(10):2469-74. PubMed ID: 26111351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival.
    Antonarakis ES; Small EJ; Petrylak DP; Quinn DI; Kibel AS; Chang NN; Dearstyne E; Harmon M; Campogan D; Haynes H; Vu T; Sheikh NA; Drake CG
    Clin Cancer Res; 2018 Oct; 24(19):4662-4671. PubMed ID: 29858218
    [No Abstract]   [Full Text] [Related]  

  • 26. Molecular insights into the development of T cell-based immunotherapy for prostate cancer.
    Dong B; Minze LJ; Xue W; Chen W
    Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
    Garcia JA; Dreicer R
    Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.
    Madan RA; Antonarakis ES; Drake CG; Fong L; Yu EY; McNeel DG; Lin DW; Chang NN; Sheikh NA; Gulley JL
    J Natl Cancer Inst; 2020 Jun; 112(6):562-573. PubMed ID: 32145020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
    Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
    Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.
    GuhaThakurta D; Sheikh NA; Fan LQ; Kandadi H; Meagher TC; Hall SJ; Kantoff PW; Higano CS; Small EJ; Gardner TA; Bailey K; Vu T; DeVries T; Whitmore JB; Frohlich MW; Trager JB; Drake CG
    Clin Cancer Res; 2015 Aug; 21(16):3619-30. PubMed ID: 25649018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.
    Sonpavde G; Di Lorenzo G; Higano CS; Kantoff PW; Madan R; Shore ND
    Eur Urol; 2012 Apr; 61(4):639-47. PubMed ID: 22036643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.
    Cheever MA; Higano CS
    Clin Cancer Res; 2011 Jun; 17(11):3520-6. PubMed ID: 21471425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.
    Thara E; Dorff TB; Pinski JK; Quinn DI
    Maturitas; 2011 Aug; 69(4):296-303. PubMed ID: 21621934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.
    Paller CJ; Antonarakis ES
    Hum Vaccin Immunother; 2012 Apr; 8(4):509-19. PubMed ID: 22336881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer immunotherapy: sipuleucel-T and beyond.
    Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
    Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.
    Holl EK; McNamara MA; Healy P; Anand M; Concepcion RS; Breland CD; Dumbudze I; Tutrone R; Shore N; Armstrong AJ; Harrison M; Wallace JA; Wu Y; George DJ
    Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):588-592. PubMed ID: 30980027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence.
    Hu R; George DJ; Zhang T
    Ther Adv Urol; 2016 Aug; 8(4):272-278. PubMed ID: 27928429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune response to sipuleucel-T in prostate cancer.
    Thara E; Dorff TB; Averia-Suboc M; Luther M; Reed ME; Pinski JK; Quinn DI
    Cancers (Basel); 2012 Apr; 4(2):420-41. PubMed ID: 24213318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.